Capricor Therapeutics Inc. has announced new research results demonstrating a scalable framework for loading therapeutic oligonucleotides, specifically siRNAs and phosphorodiamidate morpholino oligomers (PMOs), into exosomes. The findings were presented at the 2025 American Association for Extracellular Vesicles (AAEV) Annual Meeting. The research highlights the successful use of optimized electroporation techniques to load exosomes derived from 293F cells, with both scale-up and scale-out strategies achieving efficient loading comparable to standard methods. This scalable approach enables the production of clinically relevant quantities of engineered exosomes, supporting future clinical development in exosome-based therapeutics.